Financials in USD. Standardized financial statements.
A compact view of how Cyclo Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.08M | $1.38M | $1.59M | $903,376 | $1.01M | $1.01M | $1.24M | $1.50M | $950,455 | $1.57M |
| Revenue Growth? | -21.8% | -13.2% | +75.5% | -10.3% | -0.4% | -18.3% | -17.6% | +58.1% | -39.4% | 0.0% |
| Cost of Revenue? | $98,458 | $138,929 | $156,080 | $66,398 | $75,493 | $105,026 | $132,918 | $198,429 | $124,425 | $272,641 |
| Gross Profit? | $977,947 | $1.24M | $1.43M | $836,978 | $931,705 | $906,451 | $1.10M | $1.30M | $826,030 | $1.29M |
| Gross Margin? | +90.9% | +89.9% | +90.2% | +92.7% | +92.5% | +89.6% | +89.3% | +86.8% | +86.9% | +82.6% |
| Operating Expenses? | $21.04M | $16.85M | $15.70M | $9.80M | $8.32M | $5.16M | $4.95M | $4.65M | $3.09M | $1.86M |
| Operating Income? | -$20.05M | -$15.61M | -$14.27M | -$8.96M | -$7.39M | -$4.27M | -$3.84M | -$4.21M | -$2.41M | -$562,314 |
| EBITDA? | -$20.03M | -$15.60M | -$14.27M | -$8.95M | -$7.39M | -$4.24M | -$3.82M | -$4.09M | -$2.23M | -$406,568 |
| Income Before Tax | -$20.06M | -$15.45M | -$14.29M | -$8.94M | -$7.53M | -$4.26M | -$3.83M | -$4.22M | -$2.43M | -$592,687 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $11,773 | $0 | $28,603 | $120,000 | $0 |
| Net Income? | -$20.06M | -$15.28M | -$14.31M | -$8.92M | -$7.67M | -$4.26M | -$3.83M | -$4.22M | -$2.55M | -$592,687 |
| EPS? | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 | $-5.20 | $-5.32 | $-6.67 | $-4.54 | $-1.17 |
| Diluted EPS? | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 | $-5.20 | $-5.32 | $-6.67 | $-4.54 | $-1.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality